AC Immune (ACIU) – Investment Analysts’ Weekly Ratings Changes

AC Immune (NASDAQ: ACIU) recently received a number of ratings updates from brokerages and research firms:

• 11/5/2026 – AC Immune is now covered by HC Wainwright. They set a “strong-buy” rating on the stock.
• 11/3/2026 – AC Immune was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 10/28/2026 – AC Immune was downgraded by Zacks Research from “strong-buy” to “hold”.
• 10/20/2026 – AC Immune was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/2/2026 – AC Immune was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/29/2026 – AC Immune was upgraded by Zacks Research from “hold” to “strong-buy”.
• 9/24/2026 – AC Immune had its “buy” rating reaffirmed by HC Wainwright.
• 9/23/2026 – AC Immune had its “buy” rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.

AC Immune Stock Up 9.4%

AC Immune stock traded up $0.21 during midday trading on Monday, reaching $2.44. 469,280 shares of the stock traded hands, compared to its average volume of 267,160. The stock’s fifty day moving average is $2.54 and its 200-day moving average is $2.70. AC Immune has a 12 month low of $2.02 and a 12 month high of $3.90. The stock has a market cap of $248.32 million, a P/E ratio of -4.88 and a beta of 1.64.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The business had revenue of $3.88 million for the quarter, compared to the consensus estimate of $1.62 million. AC Immune had a negative return on equity of 105.25% and a negative net margin of 181.38%. On average, equities analysts predict that AC Immune will post -0.54 EPS for the current fiscal year.

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.